At a glance
ClinicalIndex Comparison Record- ✓Histologically proven intermediate- or high-grade non-Hodgkin's lymphoma
- ✓Ann Arbor classification of "bulky" stage II, III, or IV
- ✓Classified as high-intermediate or high-risk according to International Age Adjusted Index
- ✓Bidimensionally measurable disease
- ✕Lymphoblastic, transformed, or mantle cell lymphomas
- ✕CNS involvement by lymphoma
- ✕Prior lymphoma, Hodgkin's lymphoma, myelodysplastic syndromes, or leukemia
- ✕Prior chemotherapy for lymphoma except single course of CHOP/CHOP-R
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SWOG-9704 A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant) for Patients With Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups
In Brief
A Phase 3 clinical trial evaluating rituximab, CHOP regimen, and 9 other interventions for Lymphoma. Completed, enrolled 397 participants across 15 sites in 2 countries.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and radiation and kill more cancer cells. It is not yet known whether chemoradiotherapy plus peripheral stem cell transplantation is more effective than combination chemotherapy alone in treating non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying chemoradiotherapy and peripheral stem cell transplantation to see how well they work compared to combination chemotherapy in treating patients with stage II, stage III, or stage IV non-Hodgkin's lymphoma.
Study Details
Timeline
Interventions
375 mg/m2 IV every 21 days